Man Group plc Takes $5.75 Million Position in PROCEPT BioRobotics Corporation $PRCT

Man Group plc purchased a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 254,845 shares of the company’s stock, valued at approximately $5,754,000. Man Group plc owned about 0.44% of PROCEPT BioRobotics at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of PRCT. Caitong International Asset Management Co. Ltd boosted its stake in PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after purchasing an additional 746 shares during the period. Versant Capital Management Inc increased its stake in PROCEPT BioRobotics by 994.5% in the second quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after purchasing an additional 1,084 shares during the period. Center for Financial Planning Inc. acquired a new position in PROCEPT BioRobotics in the fourth quarter valued at $40,000. US Bancorp DE raised its holdings in shares of PROCEPT BioRobotics by 175.7% in the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after buying an additional 1,079 shares during the last quarter. Finally, Cache Advisors LLC purchased a new stake in shares of PROCEPT BioRobotics in the first quarter valued at about $42,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

Insider Activity

In other PROCEPT BioRobotics news, CEO Larry L. Wood purchased 23,900 shares of the stock in a transaction on Friday, August 7th. The stock was bought at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the acquisition, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 1,000 shares of company stock worth $28,480 in the last 90 days. 4.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on PRCT shares. Leerink Partners cut PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $31.00 to $29.00 in a research report on Thursday, June 11th. Wells Fargo & Company lowered PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 target price on the stock. in a report on Wednesday, August 5th. Jefferies Financial Group restated a “hold” rating and set a $20.00 price target on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Robert W. Baird set a $20.00 price target on PROCEPT BioRobotics in a report on Wednesday, August 5th. Finally, Piper Sandler lowered their price objective on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.00.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ:PRCT opened at $20.83 on Friday. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -10.74 and a beta of 0.89. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. The business’s 50 day simple moving average is $20.32 and its 200-day simple moving average is $23.93. PROCEPT BioRobotics Corporation has a 12 month low of $16.67 and a 12 month high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business had revenue of $94.50 million for the quarter, compared to analysts’ expectations of $92.77 million. During the same quarter last year, the business posted ($0.35) earnings per share. The business’s revenue was up 19.3% compared to the same quarter last year. As a group, equities analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms, including Kaplan Fox, Rosen Law Firm and Hagens Berman, announced or reiterated that a securities class action has been filed on behalf of investors who purchased PROCEPT shares from February 28, 2024, through February 25, 2026. Investors seeking to serve as lead plaintiff must act by September 22, 2026. Kaplan Fox class-action notice
• Negative Sentiment: The complaint reportedly alleges that PROCEPT understated weakness in unit handpiece sales and failed to disclose elevated customer inventory, while using repeated late-quarter bulk discounts to pull demand forward. The allegations concern potential violations of federal securities laws and could increase litigation costs, reputational risk and investor uncertainty; they have not been proven in court. Hagens Berman PROCEPT investor alert
• Negative Sentiment: The unusually high number of law-firm solicitations over the past two days keeps attention focused on the lawsuit and the company’s prior sales and inventory disclosures. Although the notices do not introduce a new financial result or regulatory action, continued headlines may weigh on sentiment and limit the stock’s recovery.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.